RU2599785C3 - Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина - Google Patents
Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диаминаInfo
- Publication number
- RU2599785C3 RU2599785C3 RU2013132947A RU2013132947A RU2599785C3 RU 2599785 C3 RU2599785 C3 RU 2599785C3 RU 2013132947 A RU2013132947 A RU 2013132947A RU 2013132947 A RU2013132947 A RU 2013132947A RU 2599785 C3 RU2599785 C3 RU 2599785C3
- Authority
- RU
- Russia
- Prior art keywords
- crystalline form
- phenyl
- weight
- less
- total impurities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (9)
1. Кристаллическая форма А 5-хлор-N2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-N4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина, проявляющая пики порошковой рентгеновской дифракции, имеющие максимумы при углах дифракции, выбранные из 7,2°, 8,1°, 10,8°, 12,0°, 12,4°, 13,4°, 14,4°, 14,8°, 15,7°, 16,9°, 17,7°, 18,5°, 19,0°, 19,5°, 20,0°, 20,3°, 21,1°, 21,6°, 22,4°, 22,6°, 23,0°, 24,1°, 24,5°, 25,5°, 26,0°, 26,2°, 27,0°, 27,3°, 28,3°, 29,0°, 29,1°, 30,6°, 31,3°, 32,8°, 33,5°, 34,2° и 36,4° (2θ градусов).
2. Кристаллическая форма по п. 1, имеющая температуру плавления 174°С как определено дифференциальной сканирующей калориметрией.
3. Кристаллическая форма по п. 1, имеющая температуру разложения выше 250°С и потерю веса при сушке, равную 0,1% при 200°С, как определено термогравиметрическим анализом.
4. Кристаллическая форма по п. 1, имеющая характеристические полосы поглощения инфракрасного излучения при 3440,4, 3318,9, 2973,7, 2931,3, 2921,7, 1596,8, 1562,1, 1498,4, 1442,5, 1409,7, 1382,7, 1311,4, 1284,4, 1270,9, 1251,6, 1224,6, 1139,7, 1126,2, 1139,7, 1126,2, 1105,0, 1081,9, 1049,1, 1020,2, 1012,5, 952,7, 937,3, 894,8, 877,5, 860,1, 848,5, 817,7, 798,4, 781,0, 763,7, 756,0, 732,8, 686,6, 665,3, 644,1, 586,3 и 543,8 (в единицах волновых чисел, см-1).
5. Кристаллическая форма по п. 1, имеющая менее 1,0% по массе общих примесей.
6. Кристаллическая форма по п. 1, имеющая менее 0,5% по массе общих примесей.
7. Кристаллическая форма по п. 1, имеющая менее 0,1% по массе общих примесей.
8. Фармацевтическая композиция для применения для лечения расстройств, опосредованных киназой анапластической лимфомы, содержащая терапевтически эффективное количество кристаллической формы по п. 1 и фармацевтически приемлемый носитель.
9. Применение кристаллической формы 5-хлор-N2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-N4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина по любому из пп. 1-7 для получения лекарственного средства для лечения расстройств, опосредованных киназой анапластической лимфомы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424194P | 2010-12-17 | 2010-12-17 | |
| US61/424,194 | 2010-12-17 | ||
| PCT/US2011/065030 WO2012082972A1 (en) | 2010-12-17 | 2011-12-15 | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016136823A Division RU2746159C2 (ru) | 2010-12-17 | 2011-12-15 | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2013132947A RU2013132947A (ru) | 2015-01-27 |
| RU2599785C2 RU2599785C2 (ru) | 2016-10-20 |
| RU2599785C3 true RU2599785C3 (ru) | 2019-04-24 |
Family
ID=45464892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013132947A RU2599785C3 (ru) | 2010-12-17 | 2011-12-15 | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина |
| RU2016136823A RU2746159C2 (ru) | 2010-12-17 | 2011-12-15 | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016136823A RU2746159C2 (ru) | 2010-12-17 | 2011-12-15 | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9309229B2 (ru) |
| EP (3) | EP3121171B1 (ru) |
| JP (1) | JP5916752B2 (ru) |
| KR (4) | KR20190022903A (ru) |
| CN (7) | CN114989139A (ru) |
| AR (2) | AR084309A1 (ru) |
| AU (1) | AU2011343775B2 (ru) |
| BR (1) | BR112013015000A2 (ru) |
| CA (1) | CA2821102C (ru) |
| CL (1) | CL2013001723A1 (ru) |
| CO (1) | CO6801792A2 (ru) |
| CY (2) | CY1119474T1 (ru) |
| DK (2) | DK3121171T3 (ru) |
| EC (1) | ECSP13012770A (ru) |
| ES (3) | ES2696526T3 (ru) |
| GT (1) | GT201300153A (ru) |
| HR (2) | HRP20171477T1 (ru) |
| HU (1) | HUE041845T2 (ru) |
| IL (1) | IL226474A (ru) |
| LT (2) | LT2651918T (ru) |
| MA (1) | MA34771B1 (ru) |
| MX (1) | MX338210B (ru) |
| MY (2) | MY164810A (ru) |
| NZ (1) | NZ610713A (ru) |
| PE (1) | PE20140698A1 (ru) |
| PL (2) | PL2651918T3 (ru) |
| PT (2) | PT3121171T (ru) |
| RS (1) | RS57771B1 (ru) |
| RU (2) | RU2599785C3 (ru) |
| SG (2) | SG190856A1 (ru) |
| SI (2) | SI3121171T1 (ru) |
| TN (1) | TN2013000216A1 (ru) |
| TW (2) | TWI576343B (ru) |
| WO (1) | WO2012082972A1 (ru) |
| ZA (1) | ZA201303599B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG190856A1 (en) * | 2010-12-17 | 2013-07-31 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| BR112015010221B1 (pt) | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105294649B (zh) * | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| CN105294650A (zh) * | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| KR102331856B1 (ko) | 2014-10-21 | 2021-11-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| CN105601614A (zh) * | 2014-11-21 | 2016-05-25 | 奥浦顿（上海）医药科技有限公司 | 一种色瑞替尼晶型及其制备方法 |
| WO2016082795A1 (zh) * | 2014-11-28 | 2016-06-02 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型i及其制备方法 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016108123A2 (en) * | 2014-12-17 | 2016-07-07 | Dr. Reddy’S Laboratories Limited | Pure amorphous and amorphous solid dispersion of ceritinib |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2017016529A1 (en) | 2015-07-28 | 2017-02-02 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) * | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| WO2017152858A1 (zh) * | 2016-03-11 | 2017-09-14 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型及其制备方法 |
| WO2017158619A1 (en) | 2016-03-15 | 2017-09-21 | Natco Pharma Limited | A modified process for the preparation of ceritinib and amorphous form of ceritinib |
| JP2019196359A (ja) * | 2019-06-17 | 2019-11-14 | ノバルティス アーゲー | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 |
| GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| EP4092021A4 (en) * | 2020-01-17 | 2023-01-25 | Shandong Xuanzhu Pharma Co., Ltd. | CRYSTALLINE FORM OF A POLYCYCLIC ANAPLASIC LYMPHOMA KINASE INHIBITOR |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| MX2009006081A (es) * | 2006-12-08 | 2009-06-17 | Irmc Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
| SI2091918T1 (sl) * | 2006-12-08 | 2015-01-30 | Irm Llc | Spojine in sestavki kot inhibitorji protein-kinaze |
| KR101174201B1 (ko) * | 2007-08-28 | 2012-08-16 | 아이알엠 엘엘씨 | 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체 |
| WO2009032694A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| CA2720946C (en) | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| HUE035029T2 (en) * | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
| WO2010142766A2 (en) * | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| NZ612788A (en) | 2010-12-17 | 2015-10-30 | Reata Pharmaceuticals Inc | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| SG190856A1 (en) * | 2010-12-17 | 2013-07-31 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| EP2651219A2 (en) | 2010-12-17 | 2013-10-23 | E.I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| CN105294650A (zh) | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| DE112015005255B4 (de) | 2014-11-21 | 2023-10-26 | Joyson Safety Systems Acquisition Llc | Airbagmodul |
| CN105622577A (zh) | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| JP2017537927A (ja) | 2014-12-04 | 2017-12-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2017016529A1 (en) | 2015-07-28 | 2017-02-02 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
-
2011
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-15 PL PL11806079T patent/PL2651918T3/pl unknown
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/zh active Pending
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en active Application Filing
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/hu unknown
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 SI SI201131583T patent/SI3121171T1/sl unknown
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 ES ES16167355T patent/ES2696526T3/es active Active
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/zh active Pending
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/lt unknown
- 2011-12-15 MX MX2013006952A patent/MX338210B/es active IP Right Grant
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 PL PL16167355T patent/PL3121171T3/pl unknown
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/ko active Search and Examination
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/ko not_active Application Discontinuation
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/es active Active
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/zh active Pending
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/es not_active Application Discontinuation
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/ru active Protection Beyond IP Right Term
- 2011-12-15 PT PT16167355T patent/PT3121171T/pt unknown
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/zh active Pending
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/lt unknown
- 2011-12-15 PT PT118060797T patent/PT2651918T/pt unknown
- 2011-12-15 SI SI201131289T patent/SI2651918T1/sl unknown
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/ja active Active
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/ko not_active Application Discontinuation
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/ru active
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/zh active Pending
- 2011-12-15 AR ARP110104703A patent/AR084309A1/es not_active Application Discontinuation
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/zh active Pending
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 RS RS20181240A patent/RS57771B1/sr unknown
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/ko active IP Right Grant
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/pt not_active Application Discontinuation
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/zh active Pending
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-15 ES ES18186197T patent/ES2905973T3/es active Active
- 2011-12-16 TW TW100146987A patent/TWI576343B/zh active
- 2011-12-16 TW TW105112710A patent/TWI576344B/zh active
-
2013
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/fr unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/es unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/es unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/fr unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/es not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/es unknown
-
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
-
2017
- 2017-10-03 HR HRP20171477TT patent/HRP20171477T1/hr unknown
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/el unknown
-
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/hr unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/el unknown
-
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| JP2013237682A5 (ru) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| RU2556206C3 (ru) | Кристаллы | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| RU2009136593A (ru) | Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших | |
| JP2020511467A5 (ru) | ||
| RU2598606C3 (ru) | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она | |
| ES2613716T3 (es) | Formas cristalinas de un derivado de purina | |
| JP2007532560A5 (ru) | ||
| JP2012176975A5 (ru) | ||
| JP2013545812A5 (ru) | ||
| CA2776342C (en) | Agomelatine and pharmaceutical compositions thereof | |
| JP2015522589A5 (ru) | ||
| JP2020536893A5 (ru) | ||
| JP2015522037A5 (ru) | ||
| JP2018531280A5 (ru) | ||
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| JP2009534373A5 (ru) | ||
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| RU2012140431A (ru) | Стабильная кристаллическая форма 2-этил-3,7-диметил-6-(4-(трифторметокси) фенокси) хинолин-4-илметилкарбоната, способ ее получения и агрохимическая композиция, содержащая данную кристаллическую форму | |
| JP2013520424A5 (ru) | ||
| WO2016051393A3 (en) | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof | |
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20190424 |